- Home
- NET vs REGN Comparison
NET vs REGN Comparison
Compare NET & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NET
- REGN
- Stock Information
- Founded
- NET 2009
- REGN 1988
- Country
- NET United States
- REGN United States
- Employees
- NET N/A
- REGN N/A
- Industry
- NET Computer Software: Prepackaged Software
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NET Technology
- REGN Health Care
- Exchange
- NET Nasdaq
- REGN Nasdaq
- Market Cap
- NET 58.8B
- REGN 63.4B
- IPO Year
- NET 2019
- REGN 1991
- Fundamental
- Price
- NET $179.21
- REGN $508.90
- Analyst Decision
- NET Buy
- REGN Buy
- Analyst Count
- NET 27
- REGN 23
- Target Price
- NET $142.19
- REGN $854.26
- AVG Volume (30 Days)
- NET 3.3M
- REGN 1.5M
- Earning Date
- NET 07-31-2025
- REGN 07-31-2025
- Dividend Yield
- NET N/A
- REGN 0.35%
- EPS Growth
- NET N/A
- REGN 16.49
- EPS
- NET N/A
- REGN 39.43
- Revenue
- NET $1,770,111,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- NET $26.85
- REGN N/A
- Revenue Next Year
- NET $26.49
- REGN $6.83
- P/E Ratio
- NET N/A
- REGN $12.92
- Revenue Growth
- NET 27.79
- REGN 7.52
- 52 Week Low
- NET $69.26
- REGN $476.49
- 52 Week High
- NET $184.85
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- NET 68.42
- REGN 41.90
- Support Level
- NET $167.13
- REGN $503.25
- Resistance Level
- NET $181.80
- REGN $538.20
- Average True Range (ATR)
- NET 6.58
- REGN 15.52
- MACD
- NET -0.98
- REGN 1.72
- Stochastic Oscillator
- NET 75.03
- REGN 58.56
About NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).